Hypercalcemic Crisis: Symptoms and Emergency Management

Hypercalcemic crisis is one of those emergencies that can easily be overlooked – especially when the presentation begins nonspecifically and deteriorates insidiously. Calcium levels above 3.5 mmol/L (or above 14 mg/dL) are immediately life-threatening and require aggressive, structured management. Without treatment, malignant cardiac arrhythmias, acute renal failure, and coma are imminent. The mortality rate of untreated hypercalcemic crises is up to 50%. This article summarizes the pathophysiology, diagnostics, ECG changes, and stepwise emergency management – with a focus on what matters in those critical first hours.

Pathophysiology and Causes

Calcium plays a central role in neuromuscular signal transmission, cardiac impulse generation, enzyme activation, and coagulation. Ionized (free) calcium accounts for approximately 50% of total serum calcium and is the biologically active fraction. Hypercalcemia occurs when the influx or mobilization of calcium from bone exceeds the renal excretory capacity.

Most Common Causes

The two most common causes by far – responsible for over 90% of all hypercalcemias – are:

• Primary hyperparathyroidism (pHPT): Most common cause in the outpatient setting. Usually caused by a solitary parathyroid adenoma. PTH is inappropriately elevated in the presence of elevated calcium. A crisis is often triggered by dehydration, immobilization, or thiazide diuretics.
• Tumor-associated hypercalcemia: Most common cause in hospitalized patients. Subtypes include:
  • Humoral hypercalcemia: Tumors secrete PTHrP (Parathyroid Hormone-related Peptide), especially squamous cell carcinomas (lung, head and neck), renal cell carcinoma, bladder carcinoma.
  • Osteolytic metastases: Direct bone destruction by metastases (breast carcinoma, multiple myeloma, bronchial carcinoma).
  • Lymphomas: Occasionally through ectopic calcitriol production (1,25-dihydroxyvitamin D).

Less Common Causes

• Granulomatous diseases (sarcoidosis, tuberculosis) through unregulated 1,25-(OH)₂-vitamin D synthesis in macrophages
• Vitamin D intoxication or excessive calcium supplementation
• Immobilization (especially in children and adolescents with high bone turnover)
• Thyrotoxicosis
• Adrenal insufficiency (Addisonian crisis)
• Pheochromocytoma (MEN-2 association)
• Milk-alkali syndrome (excessive intake of calcium and antacids)
• Drug-related: thiazides, lithium, vitamin A intoxication

Clinical Presentation

The classic mnemonic "Stones, Bones, Groans, Moans and Psychic Overtones" aptly describes the spectrum:

Gastrointestinal ("Groans")

• Nausea, vomiting, constipation
• Pancreatitis (rare but relevant)
• Peptic ulcers

Renal ("Stones")

• Polyuria and polydipsia (nephrogenic diabetes insipidus due to concentrating defect)
• Nephrolithiasis, nephrocalcinosis
• Acute renal failure due to dehydration and tubular damage
• Volume depletion → vicious cycle: further calcium retention

Osseous ("Bones")

• Bone pain, pathological fractures
• Osteitis fibrosa cystica (in severe pHPT)

Neuropsychiatric ("Moans" and "Psychic Overtones")

• Fatigue, muscle weakness, hyporeflexia
• Confusion, psychomotor slowing
• Altered consciousness progressing to coma
• Depression, psychosis

Cardiovascular

• Hypertension
• Shortened QT interval on ECG
• Brady- and tachyarrhythmias
• Enhanced digitalis toxicity (CAUTION in patients on digitalis!)

Classification of Hypercalcemia by Severity

Severity	Total calcium (corrected)	Ionized calcium	Clinical presentation
Mild	2.65–3.0 mmol/L	1.35–1.50 mmol/L	Often asymptomatic
Moderate	3.0–3.5 mmol/L	1.50–1.80 mmol/L	Symptomatic, outpatient management possible
Severe / Crisis	> 3.5 mmol/L	> 1.80 mmol/L	Life-threatening, ICU admission

Important: In hypoalbuminemia, total calcium must be corrected:

Corrected Ca²⁺ = Measured Ca²⁺ + 0.02 × (40 − Albumin in g/L)

When in doubt – and especially in the acute setting – ionized calcium measurement (blood gas analysis) is the more reliable parameter.

ECG Changes

ECG assessment is indispensable in hypercalcemia and can point in the right direction even before laboratory confirmation:

• Shortened QT interval (or QTc): Earliest and most common sign. Results from accelerated repolarization.
• Widened T-wave or flattened T-wave
• ST elevations (pseudo-infarction pattern possible)
• Prolonged PR interval (first-degree AV block)
• Widened QRS complex in severe hypercalcemia
• J-wave (Osborn wave) – rare
• At levels > 4.0 mmol/L: Bradycardia, higher-degree AV block, ventricular fibrillation, asystole

Clinical Pearl: In any unexplained QT shortening on ECG, hypercalcemia should be included in the differential diagnosis. The combination of QT shortening + confusion + polyuria is highly suspicious.

Emergency Diagnostics

In the acute setting, the following structured workup should be performed:

• ABG (ionized calcium – immediately available!)
• Laboratory: Total calcium, albumin, phosphate, magnesium, creatinine, urea, electrolytes
• Parathyroid hormone (PTH): Key parameter for differentiation
  • PTH elevated → pHPT, lithium, FHH
  • PTH suppressed → malignancy, vitamin D, granulomatous disease
• PTHrP when paraneoplastic etiology is suspected
• 25-OH-vitamin D and 1,25-(OH)₂-vitamin D
• 12-lead ECG (rhythm, QT interval)
• Urinalysis: Urinary calcium excretion
• Imaging: After stabilization – chest X-ray, neck/thyroid ultrasound if indicated, CT depending on clinical suspicion

Stepwise Emergency Management

Treatment of hypercalcemic crisis follows a clear stepwise approach. The first hour is decisive.

Immediate Measures (First 1–2 Hours)

1. Aggressive Volume Resuscitation

Most patients with hypercalcemic crisis are severely dehydrated (often with a 3–6 liter deficit). Volume administration is the most important initial measure:

• Balanced crystalloid solution (e.g., Ringer's lactate) or 0.9% NaCl: Initially 1000 mL/h for the first 2–4 hours, then adjust to 200–500 mL/h
• Target: Urine output of 200–300 mL/h
• Close monitoring: CVP, fluid balance, auscultation (pulmonary edema!), especially in patients with cardiac comorbidity

2. Loop Diuretics – Only After Adequate Rehydration

• Furosemide 20–40 mg IV only after adequate volume replacement
• Promotes renal calcium excretion (inhibits Ca²⁺ reabsorption in the thick ascending limb of the loop of Henle)
• CAUTION: Premature or overly aggressive diuretic administration without volume replacement worsens dehydration and hypercalcemia!
• NO thiazide diuretics – these increase calcium reabsorption

3. Monitoring

• Continuous ECG monitoring (ICU)
• Frequent checks: calcium (ionized), potassium, magnesium, sodium every 4–6 hours
• Fluid balance, urine output monitoring
• In patients on digitalis: Discontinue digitalis! Hypercalcemia massively potentiates digitalis toxicity.

Specific Therapy (Hours 2–24)

4. Bisphosphonates

Bisphosphonates inhibit osteoclast-mediated bone resorption and are the backbone of therapy for tumor-associated hypercalcemia:

• Zoledronate (zoledronic acid) 4 mg IV over 15 minutes – first-line agent
• Pamidronate 60–90 mg IV over 2–4 hours – alternative
• Onset of action: 24–72 hours (therefore no immediate effect – volume therapy remains essential!)
• Maximum effect after 4–7 days
• Duration of action: 2–4 weeks
• CAUTION in renal impairment: Dose adjustment required; zoledronate is contraindicated at GFR < 30 mL/min

5. Calcitonin

Calcitonin lowers calcium more rapidly than bisphosphonates and serves as bridging therapy:

• Calcitonin (salmon) 4–8 IU/kg body weight SC or IV every 6–12 hours
• Onset of action: 4–6 hours (fastest available calcium-lowering effect)
• Calcium reduction: moderate, approximately 0.3–0.5 mmol/L
• Tachyphylaxis after 48–72 hours (loss of efficacy) – therefore only suitable as bridging
• Well tolerated, can also be used in renal impairment

6. Glucocorticoids

Particularly effective in certain etiologies:

• Prednisolone 40–60 mg IV daily or Hydrocortisone 200 mg IV
• Indication primarily in:
  • Granulomatous diseases (sarcoidosis)
  • Lymphomas and myeloma
  • Vitamin D intoxication
• Mechanism: Inhibits intestinal calcium absorption and calcitriol production
• Onset of action: 2–5 days
• In pHPT or solid tumors with PTHrP: minimally effective

Refractory Hypercalcemia and Rescue Therapy

7. Denosumab

• RANKL antibody, 120 mg SC
• Alternative in bisphosphonate failure or severe renal impairment
• Slower onset of action but good efficacy
• Caution: Risk of severe hypocalcemia during follow-up

8. Hemodialysis

• Indications:
  • Treatment-refractory hypercalcemia
  • Acute renal failure (anuria)
  • Heart failure (when volume loading is not tolerated)
• Calcium-free or low-calcium dialysate
• Rapid and effective calcium reduction possible
• Often used as bridging until definitive therapy takes effect

9. Cinacalcet

• Calcimimetic – activates the calcium-sensing receptor
• Indication: Treatment-refractory pHPT (e.g., when surgery is not feasible)
• No role in acute crisis management, but relevant for long-term control

Treatment Algorithm at a Glance

1. Immediately: Aggressive volume resuscitation (0.9% NaCl or balanced crystalloid, 200–500 mL/h)
2. After rehydration: Furosemide 20–40 mg IV (target urine output > 200 mL/h)
3. Bridging: Calcitonin 4–8 IU/kg every 6–12 h SC/IV
4. Definitive reduction: Zoledronate 4 mg IV (effect after 24–72 h)
5. For granulomatous disease/lymphoma/vitamin D intoxication: Prednisolone 40–60 mg IV
6. If refractory/anuria/cardiac decompensation: Hemodialysis
7. Definitive treatment: Parathyroidectomy (pHPT), tumor therapy, discontinuation of offending medications

Pitfalls and Special Situations

• Hypoalbuminemia: Total calcium underestimates the true value – always use corrected or ionized calcium.
• Patients on digitalis: Hypercalcemia massively enhances digitalis effect. Discontinue digoxin immediately, maintain potassium within normal range.
• Concurrent hypokalemia and hypomagnesemia: Common due to diuresis and vomiting. Must be corrected, as they independently promote arrhythmias.
• Immobilized patients: Mobilize as early as possible – immobilization promotes bone resorption.
• Avoid intravenous phosphate infusions: Historically used, now abandoned and contraindicated due to risk of extraosseous calcifications (heart, kidney, lung).
• Rebound hypercalcemia: After discontinuation of bisphosphonates or with persistent tumor disease – plan close outpatient follow-up.

Prognosis and Disposition

The prognosis of hypercalcemic crisis depends critically on the underlying disease. In pHPT, parathyroidectomy is curative – perioperative mortality is low and the prognosis is excellent. In tumor-associated hypercalcemia, however, the prognosis is often limited: Median survival after a tumor-related hypercalcemic crisis is frequently only a few months, as it usually indicates advanced disease.

All patients with a hypercalcemic crisis must be monitored in the ICU or intermediate care unit. Close calcium, electrolyte, and renal function monitoring is essential during the first 48–72 hours.

Practical Training

Hypercalcemic crisis is a prime example of an emergency where a structured, algorithm-based approach saves lives. Confident application of the stepwise concept – from aggressive volume resuscitation through calcitonin bridging to bisphosphonate therapy – requires hands-on practice and interdisciplinary coordination. In the Emergency Physician Refresher Course by Simulation Tirol, you can train metabolic emergencies like hypercalcemic crisis in realistic simulation scenarios, refresh your knowledge, and exchange treatment strategies with colleagues. For more information, visit simulation.tirol.